Conditions: Acute Ischemic Stroke (AIS)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 36
Healthy volunteers: no

Brief summary:
The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: MCI-186 intervention 2: Placebo
Intervention descriptions: intervention 1: Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion

Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion intervention 2: Cohort1:circa 1000mg / 72-hour infusion matching placebo

Cohort2:circa 2000mg / 72-hour infusion matching placebo

Protocol document: